Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

BACKGROUND: The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progress using MEK inhibitors following disea...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Atefi, Mohammad, von Euw, Erika, Attar, Narsis, Ng, Charles, Chu, Connie, Guo, Deliang, Nazarian, Ramin, Chmielowski, Bartosz, Glaspy, John A., Comin-Anduix, Begonya, Mischel, Paul S., Lo, Roger S., Ribas, Antoni
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2011
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3237573/
https://ncbi.nlm.nih.gov/pubmed/22194965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0028973
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki